Abstract: The present disclosure relates to novel compound of Formula I, (I) or a pharmaceutically acceptable salt or solvate thereof; wherein Ra, Rb, Rc, Rd, ring A and ring B are as defined herein, pharmaceutical compositions containing same and methods for the treatment of cancer using same.

Abstract: The present disclosure relates to novel compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof; wherein R1, R2, Ra, Rb and Rc are as defined herein, pharmaceutical compositions containing same and methods for the treatment of cancer using same.

Abstract: The present disclosure relates to novel compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof; wherein R1, R2, Ra, Rb and Rc are as defined herein, pharmaceutical compositions containing same and methods for the treatment of cancer using same.

Abstract: The present application relates to the compounds of formula I (I) as well as their use for inhibiting at least one of AKT-1, FAK and PKC? and in the treatment and/or prevention of metastatic diseases.

Abstract: The present application relates to the compounds of formula I (I) as well as their use for inhibiting at least one of AKT-1, FAK and PKC? and in the treatment and/or prevention of metastatic diseases.

Abstract: Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

Abstract: Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumor tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

Abstract: Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

Abstract: Disclosed are compounds of the general formula (I): T?C?nD??(I), compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

Abstract: Disclosed in certain embodiments is a method of treating and/or mitigating prostate cancer, ovarian cancer, melanoma, colorectal cancer, breast cancer or lung cancer, comprising administering to an individual in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I): where T is optionally substituted phenyl; n is 1 to 6: C represents optionally substituted carbon; and D is imidazolyl; or a pharmaceutically acceptable salt or ester of said compound.

Abstract: Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegencrative disorders and other diseases of the central nervous system.

Abstract: The present invention relates to replication protein A (RPA) transcriptional factors. There is provided a nucleotide sequence encoding a replication protein A transcriptional activator 1 (RTB1) and a protein encoded by such a nucleotide sequence. RBT1 has a high activity and is highly transactivated in cancer cells. The sequence may be used to treat neoplastic disorders and in gene therapy.

Abstract: The present invention relates to an Extract of Echinops spinosus L (Asteraceae) and organic solvent soluble fractions of the extract that may be used in the treatment of cancer.